Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other…
Humanigen (HGEN) Stock Price, News & Analysis
Date:
More like thisRelated
Tampa RV giant Lazydays to delist from Nasdaq
Tampa-based Lazydays Holdings Inc., one of Florida’s most recognized...
Granite Geek: New Hampshire might get access to ‘balcony solar’
I had solar panels put on my roof six...
TSX Today: What to Watch for in Stocks on Monday, November 10
Despite firm gold and silver prices, Canadian stocks...
While BNB and DOT Struggle Under Market Pressure, BlockDAG’s Presale Soars Past $435M!
As market-wide fear grips the sector, the Binance Coin...